Biogen (NASDAQ:BIIB) Given New $275.00 Price Target at Oppenheimer

Biogen (NASDAQ:BIIB) had its price objective boosted by stock analysts at Oppenheimer from $250.00 to $275.00 in a report issued on Wednesday,MarketScreener reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price would suggest a potential upside of 49.80% from the company’s previous close.

A number of other equities analysts also recently commented on BIIB. Canaccord Genuity Group increased their price objective on shares of Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday. Wolfe Research set a $231.00 target price on Biogen in a report on Monday, February 9th. Truist Financial raised their target price on shares of Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a report on Monday, February 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biogen presently has a consensus rating of “Hold” and a consensus price target of $207.96.

Biogen Trading Up 0.1%

NASDAQ:BIIB opened at $183.58 on Wednesday. The company has a market cap of $26.94 billion, a P/E ratio of 20.67, a price-to-earnings-growth ratio of 1.49 and a beta of 0.15. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41. The business has a 50 day moving average price of $186.19 and a two-hundred day moving average price of $170.98. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts expect that Biogen will post 15.83 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

Several institutional investors and hedge funds have recently made changes to their positions in BIIB. Norges Bank acquired a new position in Biogen in the fourth quarter valued at approximately $464,408,000. Boston Partners bought a new stake in shares of Biogen in the 4th quarter valued at $302,815,000. Fred Alger Management LLC lifted its position in shares of Biogen by 39,074.8% during the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after acquiring an additional 796,735 shares during the period. Employees Provident Fund Board bought a new position in Biogen during the fourth quarter worth $123,931,000. Finally, Orion Porfolio Solutions LLC grew its stake in shares of Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after buying an additional 509,809 shares during the period. Institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Canaccord raised its price target on BIIB to $245 and reiterated a Buy rating, implying meaningful upside versus current levels — a bullish analyst signal that can support share gains. Canaccord raises BIIB PT to $245Article
• Positive Sentiment: FDA approved a higher‑dose SPINRAZA regimen, strengthening Biogen’s rare‑disease franchise and supporting longer‑term revenue potential from SMA treatments. FDA clears higher‑dose SPINRAZAArticle
• Neutral Sentiment: Biogen agreed to acquire Apellis for ~$5.6B in cash (plus potential contingent payments), adding commercial immunology and nephrology assets (SYFOVRE, EMPAVELI) that bolster growth strategy but require execution and integration. Biogen to buy Apellis for $5.6BArticle
• Neutral Sentiment: Market reaction: Apellis stock surged (big premium to APLS holders), validating the bid price, but the takeover effectively caps Apellis upside — an outcome analysts note while weighing Biogen’s strategic gain versus cash outlay. Apellis hits 2‑year high after Biogen dealArticle
• Negative Sentiment: A law firm launched an investor probe into the proposed Apellis sale, creating potential legal/transactional friction and additional uncertainty around deal process or pricing. Investor alert — probe into Apellis saleArticle
• Negative Sentiment: Several analysts remain cautious on Biogen (and some on Apellis), keeping Hold/neutral ratings and warning the deal may cap upside or not materially change near‑term catalysts — this analyst skepticism can weigh on BIIB near term. Analysts remain cautious despite positivesArticle

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.